Illumina said last week that it plans to acquire Avantome, a privately held company that is developing a low-cost, long-read sequencing technology, for $25 million in up-front cash and up to $35 million in contingent payments.
 
During the firm’s second-quarter conference call, Illumina President and CEO Jay Flatley said that Avantome’s technology, as a product, will have applications in both the research and diagnostic markets and will be complementary to Illumina’s Genome Analyzer. 
 

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

Two new Reproducibility Project: Cancer Biology studies have largely reproduced the original findings, ScienceInsider reports.

DNA fingerprinting could catch some sample mix-ups at pathology labs, the New York Times says.

In Cell this week: DNA methylation and T cell exhaustion, longevity in C. elegans, and more.

A Maryland police department has turned to DNA phenotyping to develop a suspect sketch, WJLA reports.